Ovarian function after the use of various hemostatic techniques during treatment for endometrioma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11469394

Enrollment

Registered

2017-12-18

Start date

2018-02-05

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compare the impact of hemostatic techniques (bipolar coagulation versus laparoscopic suture versus hemostatic matrix) during laparoscopic surgery for ovarian endometrioma on the ovarian follicular reserve Pregnancy and Childbirth Ovarian endometrioma on the ovarian follicular reserve

Interventions

Hemostatic techniques (bipolar coagulation versus laparoscopic suture versus hemostatic matrix) during laparoscopic surgery for ovarian endometrioma. The sample are divided into three

the number of coagulated points will be counted, and the time for coagulation will be measured in seconds. 2. Laparoscopic suturing with simple suture (2-0/Vicryl polyglactin absorbabl

Ethicon Inc., New Jersey, USA)

the number of sutures are recorded. 3. Hemostatic matrix (Surgicel® Original Absorbable Hemostat, Ethicon, USA).

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Age 18 to 40 years old 2. Regular menstrual cycle (21 to 35 days) 3. Unilateral ovarian cyst suggestive of endometrioma, measuring 3 to 7 cm, on ultrasound 4. Endometrioma and indication of laparoscopic surgery for cyst removal due to pelvic pain, infertility or cyst persistence

Exclusion criteria

Exclusion criteria: 1. Previous ovarian surgery 2. Endocrine dysfunction (diabetes, thyroid disorders, hyperprolactinemia, adrenal disease, polycystic ovary syndrome) 3. Use of hormones in the past 3 months 4. Suspected ovarian malignant tumor requiring oophorectomy 5. History of chemotherapy or radiotherapy 6. Coagulation disorders 7. Pregnancy 8. Autoimmune disease 9. Severe endometriosis

Design outcomes

Primary

Measure	Time frame
Anti-Mullerian hormone (AMH) measurement before surgery (1 month before surgery) and 1, 3 and 6 months after surgery	—

Secondary

Measure	Time frame
Follicle-stimulating hormone (FSH) FSH measurement before surgery (1 month before surgery) and 1, 3 and 6 months after surgery Ultrasound antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery	—

Countries

Brazil

Contacts

Public ContactRaquel Araújo

raquel.silveira@gmail.com+55 83 99305-9773

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 21, 2026